A Study of CTD402 in T-ALL/LBL Patients

ClinicalTrials.gov ID: NCT07070219

Public ClinicalTrials.gov record NCT07070219. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 23, 2026, 7:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single-Arm, Open-Label, Multi-Center, Phase 1b/ 2 Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTD402 in Participants With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) (TENACITY-01)

Study identification

NCT ID: NCT07070219
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: BIOHENG THERAPEUTICS US LLC; Industry
Enrollment: 54 participants

Conditions and interventions

Conditions

Interventions

CTD402 CAR T Cell Injection Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 6, 2025
Primary completion: Sep 29, 2028
Completion: Dec 29, 2028
Last update posted: Feb 4, 2026

2025 – 2028

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
Stanford University	Palo Alto	California	94304	Recruiting
Colorado Blood Cancer Institute	Denver	Colorado	80218	Not yet recruiting
University of Chicago	Chicago	Illinois	60637	Not yet recruiting
Mayo Clinic - Rochester	Rochester	Minnesota	55905	Not yet recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	11101	Recruiting
Montefiore Einstein Comprehensive Cancer Center	The Bronx	New York	10467	Recruiting
Sarah Cannon Research Insitute	Nashville	Tennessee	37203	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07070219, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 4, 2026 · Synced Apr 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07070219 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →